
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bak CRISPR Activation Plasmid (h) | sc-400646-ACT | 20 µg | $397.00 | |||
Bak CRISPR Activation Plasmid (h2) | sc-400646-ACT-2 | 20 µg | $397.00 |
Human BAK1 encodes Bak, a pro-apoptotic BCL-2 family effector that oligomerizes in the mitochondrial outer membrane to promote cytochrome c release and caspase activation during intrinsic apoptosis. Bak integrates stress cues such as DNA damage, ER stress, and growth factor withdrawal through BH3-only proteins, functioning alongside BAX to execute mitochondrial outer membrane permeabilization. Altered BAK1 activity can shift the balance between survival and programmed cell death, influencing tumor biology, immune homeostasis, and tissue injury responses. As a nodal regulator of apoptosis, Bak is widely studied in pathways governing mitochondrial integrity, cellular stress signaling, and sensitivity to pro-death stimuli.
Bak CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous BAK1 expression without altering the underlying DNA sequence.
Bak CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the BAK1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the BAK1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Bak expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native BAK1 locus and enabling the study of Bak-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Bak pathway restoration in tumor cells with silenced or reduced BAK1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.